Italia markets close in 8 hours 19 minutes

Silence Therapeutics plc (SLN.L)

LSE - LSE Prezzo differito. Valuta in GBp.
Aggiungi a portafoglio
512,00-15,00 (-2,85%)
Al 4:35PM BST. Mercato aperto.
Schermo intero
Chiusura precedente527,00
Aperto522,54
Denaro510,00 x 0
Lettera525,00 x 0
Min-Max giorno490,00 - 525,00
Intervallo di 52 settimane330,00 - 680,00
Volume29.114
Media Volume62.903
Capitalizzazione459,658M
Beta (5 anni mensile)1,22
Rapporto PE (ttm)N/D
EPS (ttm)-48,60
Prossima data utili12 ago 2021
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1A1.281,45
  • GlobeNewswire

    Silence Therapeutics Provides mRNAi GOLD™ Platform and Pipeline Updates at 2021 R&D Day

    Silence Therapeutics Provides mRNAi GOLD™ Platform and Pipeline Updates at 2021 R&D Day Announces plans to initiate a Phase 1 study in polycythaemia vera (PV) with SLN124, the third indication being assessed using endogenous hepcidin modulation SLN360 single-ascending dose study on-track for topline data in Q1’22 – independent review committee recommends extending follow-up period to assess potential longer duration of actionAdvancing mRNAi GOLD™ platform programs – poised to deliver 2-3 INDs pe

  • GlobeNewswire

    Silence Announces Proposed Cancellation of Admission of its Ordinary Shares to Trading on AIM and Transition of its Primary Trading Venue to the Nasdaq Global Market

    Silence Announces Proposed Cancellation of Admission of its Ordinary Shares to Trading on AIM and Transition of its Primary Trading Venue to the Nasdaq Global Market Notice of General Meeting to be held on 1 November 2021 15 October 2021 LONDON, Silence Therapeutics plc, AIM:SLN and Nasdaq:SLN ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medic

  • GlobeNewswire

    Silence Therapeutics and Hansoh Pharma Announce Collaboration to Develop Therapeutics Leveraging Silence’s mRNAi GOLD™ Platform

    Silence Therapeutics and Hansoh Pharma Announce Collaboration to Develop Therapeutics Leveraging Silence’s mRNAi GOLD™ Platform Hansoh will make a $16 million upfront cash payment and Silence has the potential to receive up to $1.3 billion in milestones Silence gains exclusive rights to two targets in all territories except the China region; Hansoh has rights to those two targets in the China region and global rights to a third target 15 October 2021 LONDON and SHANGHAI, Silence Therapeutics plc